Romero Pedro, Valmori Danila, Pittet Mikael J, Zippelius Alfred, Rimoldi Donata, Lévy Frederic, Dutoit Valérie, Ayyoub Maha, Rubio-Godoy Verena, Michielin Olivier, Guillaume Philippe, Batard Pascal, Luescher Immanuel F, Lejeune Ferdy, Liénard Danielle, Rufer Nathalie, Dietrich Pierre-Yves, Speiser Daniel E, Cerottini Jean-Charles
Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne branch, University Hospital (CHUV), Lausanne, Switzerland.
Immunol Rev. 2002 Oct;188:81-96. doi: 10.1034/j.1600-065x.2002.18808.x.
Some cancer patients mount spontaneous T- and B-cell responses against their tumor cells. Autologous tumor reactive CD8 cytolytic T lymphocyte (CTL) and CD4 T-cell clones as well as antibodies from these patients have been used for the identification of genes encoding the target antigens. This knowledge opened the way for new approaches to the immunotherapy of cancer. In this review, we describe the characterization of the structure-function properties of the melanocyte/melanoma tumor antigen Melan-A/MART-1, the assessment of the T-cell repertoire available against this antigen in healthy individuals, and the analysis of naturally acquired and/or vaccine-induced CTL responses to this antigen in patients with metastatic melanoma.
一些癌症患者会对自身肿瘤细胞产生自发的T细胞和B细胞反应。来自这些患者的自体肿瘤反应性CD8细胞溶解T淋巴细胞（CTL）和CD4 T细胞克隆以及抗体已被用于鉴定编码靶抗原的基因。这一认识为癌症免疫治疗的新方法开辟了道路。在本综述中，我们描述了黑素细胞/黑色素瘤肿瘤抗原Melan-A/MART-1的结构-功能特性表征、健康个体中针对该抗原的T细胞库评估，以及转移性黑色素瘤患者中对该抗原的自然获得性和/或疫苗诱导的CTL反应分析。
